Should I Buy MDWD? MDWD 2026 Analysis

Should You Buy Mediwound Ltd (MDWD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

17.790

1 Day change

3.31%

52 Week Range

22.500

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Not a good buy right now for an impatient trader: near-term technicals and pattern-based forecast skew bearish, and pre-market weakness adds downside risk.
Options positioning/flow is skewed bearish (puts dominant), which typically aligns with further near-term pressure.
Long-term upside exists (raised PT, capacity expansion), but current tape suggests poor timing today; I would avoid new entries now.

Technical Analysis

Trend/Momentum: MACD histogram is above 0 but positively contracting → bullish momentum is fading rather than accelerating.
RSI (6): 38.71 → leaning weak/near-oversold, but not a clear reversal signal yet.
Moving averages: Converging → indecision/transition phase; not a clean uptrend setup.
Levels: Price 17.665 is below Pivot 17.884 (bearish bias). Key support: S1 17.227, then S2 16.821. Resistance: R1 18.541.
Near-term probability skew (pattern analogs): ~70% chance of declines: -2.4% next day, -3.03% next week, -3.73% next month → unfavorable for buying immediately.

Options Data

Bearish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Sentiment: OI Put/Call 1.21 = mildly bearish positioning; Volume Put/Call 9.0 = strongly bearish day flow (note: total volume is small at 10, so it can be noisy).
Volatility: 30D IV 71.48 vs HV 46.13 → options are pricing elevated risk; IV percentile 59.76 (mid-high).
Activity: Today vs 30D avg volume 6.49x (from a low baseline); total OI 4102 with puts (2242) > calls (1860).

Technical Summary

Sell

Buy

Positive Catalysts

- Analyst support: H.C. Wainwright reiterates Buy and raised PT to $36 (from $31).
- Manufacturing expansion catalyst: new facility targeting ~6x capacity, on track for mid-2026 commercial production (supports longer-term scale narrative).
- Revenue growth: 2025/Q3 revenue +24.66% YoY; gross margin also improved.

Neutral/Negative Catalysts

- No near-term news catalysts in the last week to reverse current weakness.
- Near-term bearish setup: price below pivot with fading momentum; pre-market down -3.52%.
- Options flow skewed bearish (put-heavy volume).
- Profitability deterioration: 2025/Q3 net loss widened materially YoY and EPS fell.

Financial Performance

Latest quarter: 2025/Q3
Revenue: $5.43M, +24.66% YoY (good top-line growth trend).
Net income: -$2.65M, -74.21% YoY (loss expanded significantly).
EPS: -0.24, -75.51% YoY (earnings trend deteriorated).
Gross margin: 16.5%, up 6.11% YoY (some operating quality improvement, but not enough to offset higher losses).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent change (2025-11-21): H.C. Wainwright kept Buy and raised price target to $36 from $31.
Wall Street pro view (pros): capacity expansion and commercialization timeline can be a meaningful longer-term catalyst; revenue is growing.
Wall Street con view (cons): current fundamentals show worsening losses/EPS, and without near-term catalysts the stock can stay pressure-sensitive.
Positioning/other flows: Hedge funds Neutral (no notable trend last quarter); insiders Neutral (no notable trend last month). No recent congress trading data available; no noted politician/influential figure transactions in the provided data.

6 Analyst Rating

Wall Street analysts forecast MDWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDWD is 30 USD with a low forecast of 25 USD and a high forecast of 36 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 17.220

Low

Averages

High

Current: 17.220

Low

Averages

High

H.C. Wainwright

Buy

maintain

$31 -> $36

AI Analysis

2025-11-21

Reason

H.C. Wainwright

Price Target

$31 -> $36

AI Analysis

2025-11-21

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on MediWound to $36 from $31 and keeps a Buy rating on the shares. The company's new manufacturing facility with six-fold increased capacity is on track to begin commercial production in mid-2026, the analyst tells investors in a research note.

Oppenheimer

Outperform

downgrade

$36 -> $34

2025-06-02

Reason

Oppenheimer

Price Target

$36 -> $34

2025-06-02

downgrade

Outperform

Reason

Oppenheimer assumed coverage of MediWound with an Outperform rating with a price target of $34, down from $36. The firm notes the company's Q1 update highlighted progress across its clinical and commercial programs. Global EscharEx Phase 3 VALUE trial recruitment is underway, with most U.S. sites open, and interim data expected mid-2026. Given design similarities to Phase 2, Oppenheimer views Phase 3 as significantly derisked. MediWound's strategic collaborations and overall key opinion leader enthusiasm further validate EscharEx's clinical/commercial potential, the firm adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MDWD

Unlock Now

MDWD Should I Buy

MDWD Should I Buy

Should You Buy Mediwound Ltd (MDWD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch